Strategies to manage the adverse effects of oral morphine: An evidence-based report

被引:448
作者
Cherny, N [1 ]
Ripamonti, C
Pereira, J
Davis, C
Fallon, M
McQuay, H
Mercadante, S
Pasternak, G
Ventafridda, V
机构
[1] Shaare Zedek Med Ctr, Dept Oncol, Canc Pain & Palliat Med Serv, Jerusalem, Israel
[2] Natl Canc Inst, Rehabil & Palliat Care Div, Milan, Italy
[3] Fdn Floriani, Milan, Italy
[4] Countess Mountbatten House, Southampton, Hants, England
[5] Natl Canc Inst, Palliat Care Dept, Palermo, Italy
[6] Western Gen Hosp, Dept Palliat Care, Edinburgh, Midlothian, Scotland
[7] Univ Oxford, Churchill Oxford Radcliffe Hosp, Nuffield Dept Anaesthet, Pain Res Dept, Oxford, England
[8] Mem Sloan Kettering Canc Ctr, Dept Neurol, New York, NY 10021 USA
[9] Univ Alberta, Div Palliat Med, Edmonton, AB, Canada
关键词
D O I
10.1200/JCO.2001.19.9.2542
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Successful pain management with opioids requires that adequate analgesia be achieved without excessive adverse effects. By these criteria, a substantial minority of patients treated with oral morphine (10% to 30%) do not have a successful outcome because of (1) excessive adverse effects, (2) inadequate analgesia, or (3) a combination of both excessive adverse effects along with inadequate analgesia. The management of excessive adverse effects remains a major clinical challenge. Multiple approaches have been described to address this problem. The clinical challenge of selecting the best option is enhanced by the lack of definitive, evidence-based comparative data. Indeed, this aspect of opioid therapeutics has become a focus of substantial controversy. This study presents evidence-based recommendations for clinical-practice formulated by an Expert Working Group of the European Association of Palliative Care (EAPC) Research Network. These recommendations highlight the need for careful evaluation to distinguish between morphine adverse effects from comorbidity, dehydration, or drug interactions, and initial consideration of dose reduction (possibly by the addition of a co analgesic), If side effects persist, the clinician should consider options of symptomatic management of the adverse effect, opioid rotation, or switching route of systemic administration, The approaches are described and guidelines are provided to aid in selecting between therapeutic options. J Clin Oncol 19:2542-2554. (C) 2001 by American Society of Clinical Oncology.
引用
收藏
页码:2542 / 2554
页数:13
相关论文
共 180 条
[1]
Transdermal fentanyl versus sustained-release oral morphine in cancer pain: Preference, efficacy, and quality of life [J].
Ahmedzai, S ;
Brooks, D .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 1997, 13 (05) :254-261
[2]
Usage haloperidol for delirium in cancer patients [J].
Akechi, T ;
Uchitomi, Y ;
Okamura, H ;
Fukue, M ;
Kagaya, A ;
Nishida, A ;
Oomori, N ;
Yamawaki, S .
SUPPORTIVE CARE IN CANCER, 1996, 4 (05) :390-392
[3]
ALGAN SM, 1996, CLIN ORTHOP RELAT R, V332, P223
[4]
[Anonymous], 1996, Cancer Pain Relief
[5]
Opioid substitution to reduce adverse effects in cancer pain management [J].
Ashby, MA ;
Martin, P ;
Jackson, KA .
MEDICAL JOURNAL OF AUSTRALIA, 1999, 170 (02) :68-71
[6]
Comparative efficacy and safety of controlled-release morphine suppositories and tablets in cancer pain [J].
Babul, N ;
Provencher, L ;
Laberge, F ;
Harsanyi, Z ;
Moulin, D .
JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 38 (01) :74-81
[7]
DISPOSITION OF MORPHINE AND ITS GLUCURONIDE METABOLITES AFTER ORAL AND RECTAL ADMINISTRATION - EVIDENCE OF ROUTE SPECIFICITY [J].
BABUL, N ;
DARKE, AC .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1993, 54 (03) :286-292
[8]
AGE AND THE PHARMACOKINETICS OF MORPHINE [J].
BAILLIE, SP ;
BATEMAN, DN ;
COATES, PE ;
WOODHOUSE, KW .
AGE AND AGEING, 1989, 18 (04) :258-262
[9]
Metal stents: A new treatment of malignant ureteral obstruction [J].
Barbalias, GA ;
Siablis, D ;
Liatsikos, EN ;
Karnabatidis, D ;
Yarmenitis, S ;
Bouropoulos, K ;
Dimopoulos, J .
JOURNAL OF UROLOGY, 1997, 158 (01) :54-58
[10]
A REVIEW OF LOCAL RADIOTHERAPY IN THE TREATMENT OF BONE METASTASES AND CORD COMPRESSION [J].
BATES, T .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1992, 23 (01) :217-221